A Biowaiver is a regulatory mechanism that allows for the waiver of in vivo bioequivalence studies for certain drug products, typically when bioequivalence can be demonstrated through alternative methods such as in vitro dissolution testing. This approach is particularly significant in the context of generic drug development and regulatory submissions. https://www.ddregpharma.com/what-is-a-biowaiver